deferoxamine mesylate for injection, USP Principal Display Panel

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRINCIPAL DISPLAY PANEL - 500 mg Vial Label

Single-dose Vial
Rx only

Deferoxamine
Mesylate
for Injection, USP

500 mg/vial

INTRAVENOUS,
INTRAMUSCULAR, SUBCUTANEOUS USE

Distributed by
Hospira, Inc., Lake Forest, IL 60045 USA

PRINCIPAL DISPLAY PANEL - 500 mg Vial Label

PRINCIPAL DISPLAY PANEL - 500 mg Vial Carton

4 Single-dose Vials
Rx only
NDC 0409-2336-10
Contains 4 of NDC 0409-2336-01

Deferoxamine Mesylate
for Injection, USP

500 mg/vial

Hospira

Each vial contains deferoxamine mesylate USP, 500 mg in
lyophilized form.
INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS USE
Discard unused portion.

PRINCIPAL DISPLAY PANEL - 500 mg Vial Carton

PRINCIPAL DISPLAY PANEL - 2 g Vial Label

Fliptop Vial
Rx only

Deferoxamine
Mesylate
for Injection, USP

2 g/vial

For single-dose only.

For S.C., I.M. or I.V. Use

PRINCIPAL DISPLAY PANEL - 2 g Vial Label

PRINCIPAL DISPLAY PANEL - 2 g Vial Carton

4 Fliptop Vials
Rx only
NDC 0409-2337-25
Contains 4 of NDC 0409-2337-15

Deferoxamine Mesylate
for Injection, USP

2 g/vial

Hospira

Each vial contains deferoxamine mesylate USP, 2 g in lyophilized form.
For subcutaneous, intramuscular or intravenous administration.
For single-dose only. Discard unused portion.

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA

PRINCIPAL DISPLAY PANEL - 2 g Vial Carton

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

deferoxamine mesylate for injection, USP Quick Finder

Pfizer samples (for eligible HCPs)

Requests for samples of prescription medications can be made by contacting Pfizer for Professionals at 1-800-505-4426 or by visiting the PfizerPro website www.pfizerpro.com.
Report an adverse event or concern about the quality of a Pfizer product

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly by visiting www.fda.gov/medwatch or by calling (800)-332-1088.
Assistance programs (for eligible patients)

Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Patients and physicians can contact RxPathways at (866) 706-2400 or visit the website for more information on these programs www.pfizerrxpathways.com.
Resources

Show All Hide All

INDICATIONS AND USAGE

Deferoxamine Mesylate for Injection, USP is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias.

...